510(k) Report

FDA product code · Clinical toxicology

Enzymatic Radiochemical Assay, Tobramycin

LDOClass II21 CFR 862.3900510(k) required3 decisions since 19830 recalls

3 FDA decisions since 1983. No recall names this code.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, clinical toxicology panel

Twenty years of LDO at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · LDO

FDA has decided no LDO device since 2007.

Median 510(k) review, days · LDO

Too few LDO 510(k)s in any year since 2007 to give a median.

Recalls per year · LDO

No recall names LDO since 2007.

Adverse event reports per year · LDO

2in 2022

2008: 12016: 12019: 12022: 2
2007high 2 (2022) · low 0 (2007)2025

MAUDE reports naming product code LDO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—01
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—01
20170—00
20180—00
20190—01
20200—00
20210—00
20220—02
20230—00
20240—00
20250—00
20260—0—
FIG. 1 — LDO by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in LDO? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Related product codes

Other codes under 21 CFR 862.3900.